These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

358 related items for PubMed ID: 29478258

  • 1. Treatment of hepatitis C virus leads to economic gains related to reduction in cases of hepatocellular carcinoma and decompensated cirrhosis in Japan.
    Younossi ZM, Tanaka A, Eguchi Y, Henry L, Beckerman R, Mizokami M.
    J Viral Hepat; 2018 Aug; 25(8):945-951. PubMed ID: 29478258
    [Abstract] [Full Text] [Related]

  • 2. Cost Effectiveness of Hepatocellular Carcinoma Surveillance After a Sustained Virologic Response to Therapy in Patients With Hepatitis C Virus Infection and Advanced Fibrosis.
    Farhang Zangneh H, Wong WWL, Sander B, Bell CM, Mumtaz K, Kowgier M, van der Meer AJ, Cleary SP, Janssen HLA, Chan KKW, Feld JJ.
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1840-1849.e16. PubMed ID: 30580095
    [Abstract] [Full Text] [Related]

  • 3. Treatment of patients waitlisted for liver transplant with all-oral direct-acting antivirals is a cost-effective treatment strategy in the United States.
    Ahmed A, Gonzalez SA, Cholankeril G, Perumpail RB, McGinnis J, Saab S, Beckerman R, Younossi ZM.
    Hepatology; 2017 Jul; 66(1):46-56. PubMed ID: 28257591
    [Abstract] [Full Text] [Related]

  • 4. A clinician's guide to the cost and health benefits of hepatitis C cure assessed from the individual patient perspective.
    McEwan P, Selvapatt N, Brown A, Thursz M, Bennett H, Webster S, Kalsekar A, Yuan Y, Brenner M, Gordon J.
    Eur J Gastroenterol Hepatol; 2017 Feb; 29(2):208-214. PubMed ID: 27832039
    [Abstract] [Full Text] [Related]

  • 5. Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia.
    Sievert W, Razavi H, Estes C, Thompson AJ, Zekry A, Roberts SK, Dore GJ.
    J Gastroenterol Hepatol; 2014 Aug; 29 Suppl 1():1-9. PubMed ID: 25055928
    [Abstract] [Full Text] [Related]

  • 6. Impact of All-Oral Direct-Acting Antivirals on Clinical and Economic Outcomes in Patients With Chronic Hepatitis C in the United States.
    Park H, Wang W, Henry L, Nelson DR.
    Hepatology; 2019 Mar; 69(3):1032-1045. PubMed ID: 30289989
    [Abstract] [Full Text] [Related]

  • 7. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.
    Prenner SB, VanWagner LB, Flamm SL, Salem R, Lewandowski RJ, Kulik L.
    J Hepatol; 2017 Jun; 66(6):1173-1181. PubMed ID: 28161470
    [Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness and health-related outcomes of screening for hepatitis C in Korean population.
    Kim KA, Chung W, Choi HY, Ki M, Jang ES, Jeong SH.
    Liver Int; 2019 Jan; 39(1):60-69. PubMed ID: 29998565
    [Abstract] [Full Text] [Related]

  • 9. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
    Alavi M, Law MG, Valerio H, Grebely J, Amin J, Hajarizadeh B, Selvey C, George J, Dore GJ.
    J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
    [Abstract] [Full Text] [Related]

  • 10. In an era of highly effective treatment, hepatitis C screening of the United States general population should be considered.
    Younossi Z, Blissett D, Blissett R, Henry L, Younossi Y, Beckerman R, Hunt S.
    Liver Int; 2018 Feb; 38(2):258-265. PubMed ID: 28719013
    [Abstract] [Full Text] [Related]

  • 11. The value of cure associated with treating treatment-naïve chronic hepatitis C genotype 1: Are the new all-oral regimens good value to society?
    Younossi ZM, Park H, Dieterich D, Saab S, Ahmed A, Gordon SC.
    Liver Int; 2017 May; 37(5):662-668. PubMed ID: 27804195
    [Abstract] [Full Text] [Related]

  • 12. The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies.
    Duberg AS, Blach S, Falconer K, Kåberg M, Razavi H, Aleman S.
    Scand J Gastroenterol; 2015 Feb; 50(2):233-44. PubMed ID: 25515032
    [Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population.
    Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ.
    JAMA; 2003 Jul 09; 290(2):228-37. PubMed ID: 12851278
    [Abstract] [Full Text] [Related]

  • 14. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents.
    Calvaruso V, Cabibbo G, Cacciola I, Petta S, Madonia S, Bellia A, Tinè F, Distefano M, Licata A, Giannitrapani L, Prestileo T, Mazzola G, Di Rosolini MA, Larocca L, Bertino G, Digiacomo A, Benanti F, Guarneri L, Averna A, Iacobello C, Magro A, Scalisi I, Cartabellotta F, Savalli F, Barbara M, Davì A, Russello M, Scifo G, Squadrito G, Cammà C, Raimondo G, Craxì A, Di Marco V, Rete Sicilia Selezione Terapia–HCV (RESIST-HCV).
    Gastroenterology; 2018 Aug 09; 155(2):411-421.e4. PubMed ID: 29655836
    [Abstract] [Full Text] [Related]

  • 15. Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents.
    Kanwal F, Kramer J, Asch SM, Chayanupatkul M, Cao Y, El-Serag HB.
    Gastroenterology; 2017 Oct 09; 153(4):996-1005.e1. PubMed ID: 28642197
    [Abstract] [Full Text] [Related]

  • 16. Modelling the impact of improving screening and treatment of chronic hepatitis C virus infection on future hepatocellular carcinoma rates and liver-related mortality.
    Cramp ME, Rosenberg WM, Ryder SD, Blach S, Parkes J.
    BMC Gastroenterol; 2014 Aug 07; 14():137. PubMed ID: 25100159
    [Abstract] [Full Text] [Related]

  • 17. Healthcare Expenditures for the Treatment of Patients Infected with Hepatitis C Virus in Japan.
    Fukuda H, Yano Y, Sato D, Ohde S, Noto S, Watanabe R, Takahashi O.
    Pharmacoeconomics; 2020 Mar 07; 38(3):297-306. PubMed ID: 31761994
    [Abstract] [Full Text] [Related]

  • 18. The dynamic effect of direct-acting antiviral treatments on the risk of hepatocellular carcinoma in patients with cirrhosis and chronic hepatitis C.
    Lusivika-Nzinga C, Fontaine H, Dorival C, Simony M, Pol S, Carrat F, ANRS/AFEF Hepather study group.
    J Viral Hepat; 2019 Dec 07; 26(12):1489-1492. PubMed ID: 31386252
    [Abstract] [Full Text] [Related]

  • 19. Management of HCV-related decompensated cirrhosis with direct-acting antiviral agents: who should be treated?
    Hanafy AS, Bassiony MA, Basha MAA.
    Hepatol Int; 2019 Mar 07; 13(2):165-172. PubMed ID: 30758786
    [Abstract] [Full Text] [Related]

  • 20. Does antiviral therapy reduce the risk of hepatocellular carcinoma in patients with chronic hepatitis C?
    Michielsen P, Ho E, Francque S.
    Minerva Gastroenterol Dietol; 2012 Mar 07; 58(1):65-79. PubMed ID: 22419005
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.